Chris Froome insists there has been no wrongdoing on his or the team’s part with regards to an adverse analytical finding. Photo: Dario Belingheri/EPA

Four-time Tour de France champion Chris Froome, subject of an ongoing probe into an adverse doping test, will take part in the April 16-20 Tour des Alpes, it was confirmed on Wednesday.

The Kenyan-born Briton, who has this season already finished 10th in the Ruta del Sol and 34th in the Tirreno-Adriatico, will use the Tour des Alpes (formerly known as the Giro del Trentino) as his last warm-up for the Giro d’Italia, the first stage of which is scheduled for Jerusalem on May 4.

Froome’s Team Sky have dominated the Tour des Alpes in recent years, with Briton Geraint Thomas, Spain’s Mikel Landa and Australian Richie Porte having won the last three races.

The Tour this year starts in Arco and finishes with two stages in Austria, in Lienz and then Innsbruck.

The field also includes Italian champion Fabio Aru, France’s Thibaut Pinot and Colombian climber Miguel Angel Lopez.

Froome returned an adverse analytical finding for the asthma drug salbutamol at the Vuelta a Espana in September – a race he won in a historic Tour-Vuelta double.

The 32-year-old Team Sky rider is involved in a legal and scientific wrangle with the International Cycling Union’s (UCI’s) independent anti-doping unit about how that finding happened.

He insists there has been no wrongdoing on his or the team’s part.

Although salbutamol is permitted in certain doses, Froome gave a urine reading of twice the allowed limit.

The investigation is ongoing and Froome continues to compete.